Close Menu

codevelopment agreement

Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.

Group K said that the partners are developing a RT-LAMP system for use at the point of care in resource-limited areas where real-time RT-PCR is not available.

The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.

The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.

Weill Cornell will use Avalon GloboCare's exosome isolation system as part of a workflow to develop the exosomes for clinical studies.

The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.

Finland-based Tieto and Swiss firm BC Platforms will jointly develop technology for integrating genomic and clinical data in the Northern European market.

The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.

 

The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.

Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.

Pages

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.